Two pharmaceutical giants, Novo Nordisk and Eli Lilly, have seen their stock prices plummet in recent months due to concerns over efficacy uncertainty, increased competition, and political headwinds. Despite these challenges, one company stands out as a potential buy opportunity. Analysts are now eyeing Eli Lilly as the more attractive choice, with some predicting upside gains of up to 77%. The question remains: will this underappreciated stock continue its upward trajectory?
Source: https://seekingalpha.com/article/4816247-eli-lilly-vs-novo-nordisk-one-stock-is-massively-undervalued-the-other-overvalued